In a landmark paper published over two decades ago, Kerr et al. propos
ed the term apoptosis ''for a hitherto little recognized mechanism of
controlled cell, deletion, which appears to play a complementary but o
pposite role to mitosis in the regulation of animal cell populations''
(1). In the ensuing years,this natural cell death process was studied
at the basic science level, primarily with a view to understanding its
roles in cancer and in the development and maintenance off the immune
system. More recently, however, evidence has suggested a role for the
failure of normal apoptosis control in many of the major diseases of
the industrialized world. Though complex, apoptosis appears amenable t
o therapeutic intervention. The range of modern pharmaceutical strateg
ies available to treat such disregulated gene-directed processes offer
s promise for advances in the control of cancer, immune system and neu
rodegenerative disorders, heart disease, and perhaps even the aging pr
ocess itself.